Opendata, web and dolomites

PHARMS SIGNED

Bacteriophage inhibition of antibiotic-resistant pathogenic microbes and founding for novel therapeutic strategies

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 PHARMS project word cloud

Explore the words cloud of the PHARMS project. It provides you a very rough idea of what is the project "PHARMS" about.

driving    complement    haemophilus    delivered    positioned    host    worldwide    independent    screen    ways    array    strategies    peptides    levels    framework    elucidating    rational    universal    nucleotide    acinetobacter    bacteriophages    viruses    resistant    mediated    grand    confirmation    functions    group    700    isolates    genes    discover    limited    phage    discoveries    therapy    pharms    culture    revolutionary    antibiotics    infectious    validation    influenzae    bacterial    wp2    utilizes    baumannii    phages    fight    pylori    biology    time    vitro    vivo    isolate    mimic    multifaceted    discovered    battery    transport    elucidate    engineer    alien    resistance    threatening    vectors    mechanisms    therapies    therapeutic    interdisciplinary    tools    clinical    employ    inhibitors    natural    life    sequence    plan    wp3    emergence    deploy    throughput    molecular    action    ranging    diseases    unknown    transcription    treating    wp1    killed    bacteria    people    lines    translation    synthetic    building    modes    antimicrobial    enzymes    amr    bactericidal    scientific    multiple    pathogens    helicobacter    encoded    obstacles    inhibition   

Project "PHARMS" data sheet

The following table provides information about the project.

Coordinator
HELMHOLTZ ZENTRUM MUENCHEN DEUTSCHES FORSCHUNGSZENTRUM FUER GESUNDHEIT UND UMWELT GMBH 

Organization address
address: INGOLSTADTER LANDSTRASSE 1
city: NEUHERBERG
postcode: 85764
website: www.helmholtz-muenchen.de

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Germany [DE]
 Total cost 1˙499˙650 €
 EC max contribution 1˙499˙650 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2018-STG
 Funding Scheme ERC-STG
 Starting year 2019
 Duration (year-month-day) from 2019-01-01   to  2023-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    HELMHOLTZ ZENTRUM MUENCHEN DEUTSCHES FORSCHUNGSZENTRUM FUER GESUNDHEIT UND UMWELT GMBH DE (NEUHERBERG) coordinator 1˙499˙650.00

Map

 Project objective

Emergence of antimicrobial resistance (AMR) is a grand scientific challenge of our time that has killed more than 700,000 people worldwide. Phage therapy, a promising complement to antibiotics, utilizes viruses of bacteria (bacteriophages) or phage-derived inhibitors as natural ways to fight AMR. The main obstacles in the clinical application of phage-based AMR therapy are the limited number of phage isolates and the unknown molecular mechanisms of phage-delivered bactericidal action. Building on the recent advances of my group in high-throughput, culture-independent but host-targeted methodologies, PHARMS aims to deploy a revolutionary approach: to screen for all possible phages of a resistant bacterial isolate, characterize multiple lines of their bactericidal functions, and use this information for the design of a whole battery of phage-based therapies that employ multifaceted modes of action.

Using an interdisciplinary research plan, PHARMS will discover phage-specific bactericidal action modes at all possible levels ranging from nucleotide sequence and transcription to translation, in order to elucidate the molecular mechanisms driving phage-mediated inhibition of AMR Acinetobacter baumannii, Helicobacter pylori, & Haemophilus influenzae (WP1). These discoveries, together with novel synthetic biology tools, will enable us to engineer an array of phage vectors that mimic phage-deployed bactericidal modes discovered under WP1, including transport of alien genes to deliver bactericidal effects (WP2). PHARMS will provide molecular confirmation and in vitro & in vivo validation of the functions of phage-encoded bactericidal peptides and enzymes (WP3). By elucidating universal and specific mechanisms of phage-delivered inhibition of AMR pathogens, PHARMS is positioned to provide the rational framework for the design of novel therapeutic strategies aimed at treating common and life-threatening infectious diseases.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "PHARMS" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "PHARMS" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

ENUF (2019)

Evaluation of Novel Ultra-Fast selective III-V Epitaxy

Read More  

DeCoCt (2019)

Knowledge based design of complex synthetic microbial communities for plant protection

Read More  

TAMING CORROSION (2020)

Towards mastering the long-standing challenge of ageing infrastructures in corrosive environments

Read More